Ovarian Metastasis from Human Papillomavirus-associated Usual-type Endocervical Adenocarcinoma: Clinicopathological Characteristics for Distinguishing from Primary Ovarian Mucinous or Endometrioid Tumor

Overview

Journal In Vivo

Specialty Oncology

Date 2024 Jun 27

PMID 38936897

Authors

Yoon Ah Cho

Cheol Keun Park

Hyun-Soo Kim

Affiliations

Soon will be listed here.

Abstract

Background/aim: Distinguishing ovarian metastasis of usual-type endocervical adenocarcinoma (UEA) from primary ovarian tumors is often challenging because of several overlapping features. This study aimed to investigate the clinicopathological characteristics and outcomes of patients with metastatic ovarian UEA.

Patients And Methods: Clinicopathological information was collected from eight patients with metastatic ovarian UEA. Immunostaining was also performed.

Results: Most patients presented with adnexal masses that were suspected to be primary ovarian tumors. All examined cases showed block p16 positivity in paired primary and metastatic tumors. Five patients who completed post-operative chemotherapy or concurrent chemoradiotherapy (CCRT) did not experience recurrence. In contrast, one patient who refused further treatment after the first CCRT cycle experienced ovarian and peritoneal metastases. One patient with isolated ovarian metastasis left untreated and developed peritoneal metastasis during follow-up.

Conclusion: Patients with UEA who received proper management for ovarian metastases showed favorable outcomes. Given that ovarian metastatic UEA can mimic primary ovarian borderline tumor or carcinoma of the mucinous or endometrioid type, pathologists should be aware of this unusual but distinctive morphology to avoid misdiagnosis and inappropriate treatment.

Citing Articles

Clinicopathological Significance of Claudin-6 Immunoreactivity in Low-grade, Early-stage Endometrioid Endometrial Carcinoma.

Lee Y, Kim H In Vivo. 2024; 39(1):367-374.

PMID: 39740870 PMC: 11705117. DOI: 10.21873/invivo.13837.

References

Landoni F, Zanagnolo V, Lovato-Diaz L, Maneo A, Rossi R, Gadducci A . Ovarian metastases in early-stage cervical cancer (IA2-IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study). Int J Gynecol Cancer. 2007; 17(3):623-8. DOI: 10.1111/j.1525-1438.2006.00854.x. View

Stolnicu S, Park K, Kiyokawa T, Oliva E, McCluggage W, Soslow R . Tumor Typing of Endocervical Adenocarcinoma: Contemporary Review and Recommendations From the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2021; 40(Suppl 1):S75-S91. PMC: 7888380. DOI: 10.1097/PGP.0000000000000751. View

Lee S, Bae J, Lee A, Tong S, Park Y, Park J . Clinical characteristics of metastatic tumors to the ovaries. J Korean Med Sci. 2009; 24(1):114-9. PMC: 2650975. DOI: 10.3346/jkms.2009.24.1.114. View

Yamamoto R, Okamoto K, Yukiharu T, Kaneuchi M, Negishi H, Sakuragi N . A study of risk factors for ovarian metastases in stage Ib-IIIb cervical carcinoma and analysis of ovarian function after a transposition. Gynecol Oncol. 2001; 82(2):312-6. DOI: 10.1006/gyno.2001.6277. View

Sohn J, Lee Y, Kim H . Endometrioid Carcinomas of the Ovaries and Endometrium Involving Endocervical Polyps: Comprehensive Clinicopathological Analyses. Diagnostics (Basel). 2022; 12(10). PMC: 9600253. DOI: 10.3390/diagnostics12102339. View

Kim H, Kim H, Yeo M, Won K, Kim Y, Han G . Mesonephric-like Adenocarcinoma of the Uterine Corpus: Comprehensive Analyses of Clinicopathological, Molecular, and Prognostic Characteristics With Retrospective Review of 237 Endometrial Carcinoma Cases. Cancer Genomics Proteomics. 2022; 19(4):526-539. PMC: 9247884. DOI: 10.21873/cgp.20338. View

Koh H, Park E, Kim H . Mesonephric-like Adenocarcinoma of the Ovary: Clinicopathological and Molecular Characteristics. Diagnostics (Basel). 2022; 12(2). PMC: 8871294. DOI: 10.3390/diagnostics12020326. View

Kobel M, Ronnett B, Singh N, Soslow R, Gilks C, McCluggage W . Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. Int J Gynecol Pathol. 2018; 38 Suppl 1:S123-S131. PMC: 6127005. DOI: 10.1097/PGP.0000000000000488. View

Wentzensen N, du Bois A, Kommoss S, Pfisterer J, von Knebel Doeberitz M, Schmidt D . No metastatic cervical adenocarcinomas in a series of p16INK4a-positive mucinous or endometrioid advanced ovarian carcinomas: an analysis of the AGO Ovarian Cancer Study Group. Int J Gynecol Pathol. 2007; 27(1):18-23. DOI: 10.1097/pgp.0b013e318074b83f. View

10.

Vang R, Gown A, Farinola M, Barry T, Wheeler D, Yemelyanova A . p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol. 2007; 31(5):653-63. DOI: 10.1097/01.pas.0000213369.71676.25. View

11.

Bhatla N, Berek J, Cuello Fredes M, Denny L, Grenman S, Karunaratne K . Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2019; 145(1):129-135. DOI: 10.1002/ijgo.12749. View

12.

Horn L, Hohn A, Stark S, Einenkel J, Borte G, Haak A . Endocervical adenocarcinoma in situ (AIS) with ovarian and pulmonary involvement: report of a case and review of the literature suggesting a "seed and soil hypothesis". J Cancer Res Clin Oncol. 2019; 145(8):2061-2069. DOI: 10.1007/s00432-019-02966-4. View

13.

Smith H, Tiffany M, Qualls C, Key C . The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecol Oncol. 2000; 78(2):97-105. DOI: 10.1006/gyno.2000.5826. View

14.

Bae H, Kim H . Endocervical Adenocarcinoma Showing Microcystic, Elongated, and Fragmented (MELF) Pattern of Stromal Invasion: A Single-Institutional Analysis of 10 Cases with Comprehensive Clinicopathological Analyses and Ki-67 Immunostaining. Biomedicines. 2023; 11(11). PMC: 10669505. DOI: 10.3390/biomedicines11113026. View

15.

Young R, Clement P . Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. Histopathology. 2002; 41(3):185-207. DOI: 10.1046/j.1365-2559.2002.01462.x. View

16.

Kim H, Park M, Sung J, Kim Y, Kim H, Na K . Tumor-specific Expression of Insulin-like Growth Factor II mRNA-binding Protein 3 Independently Predicts Worse Survival of Patients With Adenocarcinoma of the Ampulla of Vater. Anticancer Res. 2019; 39(9):4947-4955. DOI: 10.21873/anticanres.13683. View

17.

Park S, Park E, Kim H . Mesonephric-like Carcinosarcoma of the Uterine Corpus: Clinicopathological, Molecular and Prognostic Characteristics in Comparison With Uterine Mesonephric-like Adenocarcinoma and Conventional Endometrial Carcinosarcoma. Cancer Genomics Proteomics. 2022; 19(6):747-760. PMC: 9620445. DOI: 10.21873/cgp.20357. View

18.

Elishaev E, Gilks C, Miller D, Srodon M, Kurman R, Ronnett B . Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol. 2005; 29(3):281-94. DOI: 10.1097/01.pas.0000152136.81771.12. View

19.

Na K, Sung J, Kim H . Clinicopathological Characteristics of High-grade Squamous Intraepithelial Lesions Involving Condyloma Acuminatum. Anticancer Res. 2018; 38(3):1767-1774. DOI: 10.21873/anticanres.12414. View

20.

Yoo H, Kim H . Clinicopathological and Prognostic Values of Telomerase Reverse Transcriptase () Promoter Mutations in Ovarian Clear Cell Carcinoma for Predicting Tumor Recurrence, Platinum Resistance and Survival. Cancer Genomics Proteomics. 2023; 20(6):626-636. PMC: 10614067. DOI: 10.21873/cgp.20411. View